Hillmen, P. “The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in relapsed/Refractory CLL”. Hematology Meeting Reports (formerly Haematologica Reports), vol. 1, no. 2, May 2009, doi:10.4081/hmr.v1i2.226.